Myeloid lineage-defining markers: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| (14 intermediate revisions by the same user not shown) | |||
| Line 2: | Line 2: | ||
<div style="width: 200px"> | <div style="width: 200px"> | ||
{| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy" | {| class="wikitable" style="border-left:solid 5px green;border-right:solid 5px green;border-top:solid 5px black;border-bottom:solid 5px black; font-size:90%; color:navy" | ||
| colspan="1"''|[[ | | colspan="1"''|[[Tables of diagnostic markers supporting lineage assignment in AML|Return to previous page]]'' | ||
|} | |} | ||
</div> | </div> | ||
---- | ---- | ||
'' | ''These markers can be used to identify myeloid lineage. They allow the diagnosis of AML if there are no lineage-defining markers of B-lineage or T-lineage. Alternatively, if lineage-defining markers of B-lineage or T-lineage are present then consider a diagnosis of MPAL''</br></br> | ||
<div style="width: 95%; border: 1px solid black; font-size:100%"> | |||
{| class="wikitable" style="color:black; background-color:#ffffff;" cellpadding="0" | |||
<div style="width: 95%"> | !colspan="2" <span style="font-size:90%; font-color:navy; style="text-align: left; border: 1px solid black; background:pale gray">|'''Assignment of myeloid lineage: Lineage-defining markers'''</br></span> | ||
{| class="wikitable" style=" | |- | ||
!colspan="2" style = " | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 1''' | ||
|- | |||
|colspan="1" style = "font-size:90%; color:black;" |'''Demonstrate expression of Myeloperoxidase (MPO)''' | |||
|colspan="1" style = "font-size:90%;"|[[MPO|Myeloperoxidase]] expression alone may be sufficient to establish myeloid lineage, but be aware of the limitations: '''(1)''' intensity should be at least half of that of mature neutrophils in at least of proportion of cells measured by the same method; '''(2)''' there are circumstances where judgement is required (see notes). | |||
|- | |- | ||
|colspan=" | |colspan="2" style = "font-size:90%; color:black; background:#ddeee1" |'''Marker option 2''' | ||
|- | |- | ||
|colspan="1" style = "font-size:90%; color:black;" | | |colspan="1" style = "font-size:90%; color:black;" |'''Demonstrate clear evidence of monocytic lineage''' | ||
|colspan="1" style = "font-size:90%; | |colspan="1" style = "font-size:90%;|If MPO is not demonstrated then myeloid lineage may still be assigned through demonstration of monocytic features. This can be assigned by the detection of '''at least two''' of the following features: By flow cytometry: [[CD11c]], [[CD14]], [[CD64]]; by other approaches: '''lysozyme''' or '''non-specific esterase''' in malignant cells (enzyme cytochemistry) | ||
|- | |- | ||
|} | |} | ||
</div> | </div> | ||
---- | ---- | ||
<span style="font-size:85%;>'''Notes on interpretation of MPO positivity'''</br> | |||
<span style="font-size:85%;>'''Notes on interpretation of MPO positivity | |||
The WHO classification advises that MPO expression is assessed by its intensity of expression and includes some flexibility in interpretation. The is based on several considerations:</br> | The WHO classification advises that MPO expression is assessed by its intensity of expression and includes some flexibility in interpretation. The is based on several considerations:</br> | ||
(1) The techniques used to detect MPO do not have the same sensitivity: immunohistochemistry > flow cytometry > enzyme-cytochemistry. This means diagnosis of MPAL may be method dependent – expressing MPO as intensity allows expression to be compared with that of normal cells detected using the same method.</br> | (1) The techniques used to detect MPO do not have the same sensitivity: immunohistochemistry > flow cytometry > enzyme-cytochemistry. This means diagnosis of MPAL may be method dependent – expressing MPO as intensity allows expression to be compared with that of normal cells detected using the same method.</br> | ||
Latest revision as of 19:58, 5 January 2024
These markers can be used to identify myeloid lineage. They allow the diagnosis of AML if there are no lineage-defining markers of B-lineage or T-lineage. Alternatively, if lineage-defining markers of B-lineage or T-lineage are present then consider a diagnosis of MPAL
| Assignment of myeloid lineage: Lineage-defining markers | |
|---|---|
| Marker option 1 | |
| Demonstrate expression of Myeloperoxidase (MPO) | Myeloperoxidase expression alone may be sufficient to establish myeloid lineage, but be aware of the limitations: (1) intensity should be at least half of that of mature neutrophils in at least of proportion of cells measured by the same method; (2) there are circumstances where judgement is required (see notes). |
| Marker option 2 | |
| Demonstrate clear evidence of monocytic lineage | If MPO is not demonstrated then myeloid lineage may still be assigned through demonstration of monocytic features. This can be assigned by the detection of at least two of the following features: By flow cytometry: CD11c, CD14, CD64; by other approaches: lysozyme or non-specific esterase in malignant cells (enzyme cytochemistry) |
Notes on interpretation of MPO positivity
The WHO classification advises that MPO expression is assessed by its intensity of expression and includes some flexibility in interpretation. The is based on several considerations:
(1) The techniques used to detect MPO do not have the same sensitivity: immunohistochemistry > flow cytometry > enzyme-cytochemistry. This means diagnosis of MPAL may be method dependent – expressing MPO as intensity allows expression to be compared with that of normal cells detected using the same method.
(2) MPO is not fully specific for myeloid lineage in all cases: this is particularly the case when expression is uniform and dim, so an element of subjectivity is present when interpreting (particularly when detected by more sensitive techniques such as immunocytochemistry).
(3) Context of MPO may be important: Applying a threshold of >10% cells being positive for MPO may improve specificity. Detecting variability of expression level of MPO by blast cells may suggest partial maturation and support myeloid lineage origin (often together with variable light scatter). The presence of other myeloid markers may provide greater confidence that MPO is lineage specific. Similarly, be aware of common patterns of aberrancy that are associated with specific alternative diagnoses: Dim (weak) expression of MPO may be a feature of otherwise typical B-LL/LBL; Burkitt-like entities may have strong MPO staining however other investigations will confirm their nature and other myeloid markers will be absent.